开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

重阳节翌日休市 10-16 15:57:57

1.505

-0.055

-3.53%

最高1.550	最低1.465	成交量77.25万
今开1.505	昨收1.560	日振幅5.45%
总市值7.51亿	流通市值7.51亿	总股本4.99亿
成交额116.62万	换手率0.15%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.505,"timestamp":1792137477021,"preClose":1.56,"halted":0,"volume":772500,"delay":0,"changeRate":-0.03525641025641036,"floatShares":499000000,"shares":499000000,"eps":-0.444906,"marketStatus":"重阳节翌日休市","change":-0.055,"latestTime":"10-16 15:57:57","open":1.505,"high":1.55,"low":1.465,"amount":1166190,"amplitude":0.054487,"askPrice":1.51,"askSize":127000,"bidPrice":1.475,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-0.463836,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.56,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":0.9888632873643084,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2676573601","title":"股市必读：福瑞达新发布《鲁商福瑞达医药股份有限公司关于聘任公司高级管理人员的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676573601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676573601?lang=zh_cn&edition=full","pubTime":"2026-10-19 03:19","pubTimestamp":1792351148,"startTime":"0","endTime":"0","summary":"公司公告汇总鲁商福瑞达医药股份有限公司关于聘任公司高级管理人员的公告鲁商福瑞达医药股份有限公司于2026年10月16日召开第十二届董事会2026年第三次临时会议，审议通过聘任刘飞先生、殷成强先生为公司副总经理的议案。后续如有相关计划，公司将严格按照监管要求及时对外公告。公司相关经营动态、重大举措请以公司在上交所披露的官方公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900001003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","BK1515","09939","BK0273","BK0188","BK1161","BK0229","600223"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676522484","title":"AI退潮、医药接棒？美股正在上演！港股医药反身向上，行情可持续吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2676522484","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676522484?lang=zh_cn&edition=full","pubTime":"2026-10-18 19:10","pubTimestamp":1792321800,"startTime":"0","endTime":"0","summary":"10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。早盘创新药全链反攻，港股通创新药ETF华宝、港股通医疗ETF华宝标的指数分别上探4.7%、3.9%，午后受药明系突发跳水影响涨幅收窄，但最终仍各自收涨1.94%、0.19%。近期市场风险偏好回落，获利盘集中兑现易引发情绪性杀跌。从板块整体来看，港股医药今日率先开启修复，持续性值得期待。外媒称，AI的高波动性或正推动资金重新审视大型医药股的配置价值。AI退潮，医药接棒？","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-10-18/doc-inivrzvp7220664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","CHAT","AGIX","BK1574","AIPO","159718","BK1515","ARTY","QTOC","KURE","VTHR","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676521071","title":"医药内部也不是一条赛道：大药企、创新药与CXO为何不能用同一套轮动逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2676521071","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676521071?lang=zh_cn&edition=full","pubTime":"2026-10-18 16:18","pubTimestamp":1792311480,"startTime":"0","endTime":"0","summary":"礼来、AbbVie等制药巨头股价走强，容易被概括为“资金从AI转向医药”。但股价接近高位，不等于资金已经系统性迁移：现有公开线索没有提供相关个股的具体涨幅区间、指数资金流、ETF申赎或全 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261018/c680806232.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261018/c680806232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["IBBQ","09939","159992","BK1574","159938","LNGR","BK1161","CXO","WX","06978","BK1515","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676237815","title":"AI热度与医药行情并非跷跷板：从研发投入看CXO的传导链条","url":"https://stock-news.laohu8.com/highlight/detail?id=2676237815","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676237815?lang=zh_cn&edition=full","pubTime":"2026-10-18 08:18","pubTimestamp":1792282680,"startTime":"0","endTime":"0","summary":"礼来、AbbVie等制药巨头股价走强，市场很容易把行情概括为“资金从AI转向医药”。但股价靠近高位，和资金正在系统性撤离AI，是两回事。现有公开线索没有提供相关个股的具体涨幅区间、指数资 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261018/c680804804.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261018/c680804804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","AGIX","VTHR","09939","BK1574","159938","CHAT","AIPO","CXO","ARTY","QTOC","WX","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675949564","title":"A股收评：近3300只个股飘红，沪指收涨，深指、创业板指收跌；半导体转跌，PCB、医药概念股下挫；低空经济概念股走强，贵金属、房地产上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2675949564","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675949564?lang=zh_cn&edition=full","pubTime":"2026-10-16 15:07","pubTimestamp":1792134445,"startTime":"0","endTime":"0","summary":"16日，A股三大指数高开，午后震荡下行，盘中一度集体翻绿。截至收盘，沪指涨0.24%，深证成指跌0.12%，创业板指跌0.39%。全市成交额1.57万亿元，近3300只个股上涨。板块方面，半导体高开低走转跌；PCB、医药概念股下挫，生物科技领跌，文化传媒、海运、教育、互联网跌幅居前。低空经济概念股走强，汽车、贵金属、房地产、石化、发电设备等板块上涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/1407,202610163898358728.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/1407,202610163898358728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["SOXL","YSAG","CHPY","BZZ","FTXL","399001","MQQQ","CWC","399006","TEKX","512510","02823","PCB","SSG","DRNL","SOXS","000300.SH","159967","159982","159582","WDRN","DBP","SMHX","DRNZ","PSI","TECY","000688.SH","XSD","NBDS","510880","USD","09939","000001.SH","159938","CHPS","REET","SOXQ","SOXY","512880","SMH","510300","000905.SH","09979","03188","399300","VGT","EIS","515890","SOXX","FWD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675563356","title":"港股异动 | 礼邦医药-B(09637.HK)盘中一度涨近4% 振幅达13.53% 港股创新药板块集体走强 AP308治疗IgA肾病新药临床试验获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2675563356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675563356?lang=zh_cn&edition=full","pubTime":"2026-10-16 12:47","pubTimestamp":1792126069,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1191","09637","BK1515","BK1574","09939","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675557578","title":"港股核心资产多板块共振上涨，医药与消费龙头领涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2675557578","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675557578?lang=zh_cn&edition=full","pubTime":"2026-10-16 10:33","pubTimestamp":1792117980,"startTime":"0","endTime":"0","summary":"截至10月16日10点6分，上证指数涨0.44%，深证成指涨0.29%，创业板指涨0.09%。军工装备、养鸡、教育等板块涨幅居前。 ETF方面，恒生ETF易方达(513210)涨1.06%，成分股百济神州(06160.HK)涨超 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261016/c680764325.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261016/c680764325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["159520","BK4588","BK1515","BK1574","BK4585","KCAI","09939","VXUS","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675552295","title":"港股异动 | 海致科技集团(02706.HK)涨超7% 与九州通订立战略合作框架协议 助力医药流通行业数智化转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2675552295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675552295?lang=zh_cn&edition=full","pubTime":"2026-10-16 10:21","pubTimestamp":1792117313,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1117","BK1161","09939","BK1574","02706"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675552395","title":"港股异动 | 劲方医药-B(02595)早盘涨超8% 公司公布KRAS G12D抑制剂多项临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2675552395","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675552395?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:59","pubTimestamp":1792115988,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B早盘涨超8%。截至发稿，涨4.42%，报28.38港元，成交额5032.92万港元。消息面上，10月15日，劲方医药宣布GFH375/VS-7375多项临床研究取得积极进展并公布相关研究的最新数据。目前GFH375在中国已获得中国国家药监局药品审评中心三次纳入突破性治疗品种，针对适应症分别为KRAS G12D突变型胰腺癌、非小细胞肺癌、结直肠癌，并进入单药治疗胰腺癌及NSCLC两项注册性3期研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","159938","02595","BK1161","BK4588","VXUS","KCAI","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675455420","title":"港股异动 | 剂泰科技-P(07666.HK)早盘涨近8% 医药十五五规划提出打造AI制药高价值应用场景","url":"https://stock-news.laohu8.com/highlight/detail?id=2675455420","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675455420?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:41","pubTimestamp":1792114901,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","07666","01477","BK1161","BK1191","09939","BK1515","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675546035","title":"【券商聚焦】中信建投：ESMO中国研究入选创新高 梳理医药细分板块机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2675546035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675546035?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:27","pubTimestamp":1792114033,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示，本周制药行业表现一般，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医疗器械及服务板块低值耗材表现较好，多受个股事件催化，科技概念标的调整，港股回购活跃；短期关注招标改善和集采出清，中长期看创新、出海、并购。中药板块跑赢申万医药及大盘，关注红利、创新及“四同药品”、中成药集采政策。生物制品板块跑输医药指数及大盘，AI制药、mRNA肿瘤疫苗概念股回调；南北方ILI%均环比降低，南方检测阳性率提升、北方降低。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993829","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","BK1610","LU1251922891.USD","02269","159938","LU0823426480.USD","LU0072913022.USD","01801","06185","LU2476274720.SGD","09688","KCE","LU1226287875.USD","BK1583","LU1226287792.SGD","09926","02616","LU0314109678.HKD","LU0359201612.USD","601066","KURE","LU0348827113.USD","LU1969619763.USD","09995","LU0501845795.SGD","SG9999011746.SGD","BK1500","06160","01877","01093","LU0052750758.USD","LU0128526141.USD","LU1242518857.USD","LU0348767384.USD","IE00BZ08YR35.GBP","LU0228659784.USD","LU0326950275.SGD","LU0140636845.USD","SG9999002562.SGD","LU0634319403.HKD","LU0979878070.USD","LU1951186391.HKD","BK1515","LU0417516902.SGD","LU0819121731.USD","09939","BK1141","LU0181495838.USD","02142","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675555730","title":"国药现代2026年前三季度净利预降59.30%至63.05%；美年健康2026年前三季度净利预增75.47%至92.83% | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2675555730","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675555730?lang=zh_cn&edition=full","pubTime":"2026-10-16 07:00","pubTimestamp":1792105206,"startTime":"0","endTime":"0","summary":"丨2026年10月16日星期五丨NO.1阿诺医药与礼来及德国默克达成AN4035临床试验合作及药物供应协议10月15日，阿诺医药宣布，公司已分别与礼来及德国默克就抗EGFR抗体西妥昔单抗达成临床试验合作及药物供应协议。该协议将支持阿诺医药正在开展的AN4035全球I期临床试验，公司是该试验的申办方。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610163897367824.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610163897367824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828474.EUR","BK1574","BK0028","002044","LU2097828714.EUR","BK0239","09939","LU2097828805.USD","BK0146","BK0010","BK0082","BK0196","BK0132","LU2097828557.USD","BK0020","600420","BK0114","159938","LU2097828631.EUR","BK0236","BK1161","BK1515","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675258791","title":"中哲精化：聚焦医药中间体主业培育","url":"https://stock-news.laohu8.com/highlight/detail?id=2675258791","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675258791?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:51","pubTimestamp":1792068670,"startTime":"0","endTime":"0","summary":"证券之星消息，中哲精化10月14日在投资者关系平台上答复投资者关心的问题。中哲成为控股股东以来，持续推动公司治理优化与业务转型，落地多项经营举措：聚焦医药中间体主业培育、推进新设子公司业务布局、优化尿素业务经营模式，多措并举改善经营基本面。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500037504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000953","BK1515","09939","BK0010","BK0066","BK0071","BK0077","BK0004","159938","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675302701","title":"10月15日东诚药业跌8.51%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675302701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675302701?lang=zh_cn&edition=full","pubTime":"2026-10-15 16:42","pubTimestamp":1792053734,"startTime":"0","endTime":"0","summary":"证券之星消息，10月15日东诚药业跌8.51%，收盘报12.69元，换手率3.85%，成交量28.59万手，成交额3.68亿元。银河医药混合A目前规模为3.51亿元，最新净值0.5513，较上一交易日下跌1.2%，近一年下跌7.45%。方伟在任的基金产品包括:银河康乐股票A，管理时间为2021年5月10日至今，期间收益率为-29.92%；银河医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500027662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","BK1574","159938","09939","BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675301726","title":"北向资金三季度调仓路径浮现：银行、医药板块持仓市值增幅显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2675301726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675301726?lang=zh_cn&edition=full","pubTime":"2026-10-15 15:52","pubTimestamp":1792050742,"startTime":"0","endTime":"0","summary":"随着沪深股通2026年三季度末持股数据正式出炉，北向资金在三季度的调仓动向也随之浮出水面。大规模加仓叠加股价上涨的双重效应，使得银行板块在北向资金持仓版图中的地位大幅跃升，从上季度的第六大重仓板块跃升至第三大重仓板块。三季度银行持股市值增长居首，医药生物紧随其后，持股市值增长约337亿元，增持金额约为131.15亿元。银行与医药板块的持仓市值增幅，清晰地勾勒出北向资金在三季度的调仓主线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026101500023834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161121","09939","BK1574","BK1161","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675805371","title":"劲方医药-B盘中涨超8% GFH375/VS-7375多项国内及海外临床研究取得积极进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2675805371","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675805371?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:53","pubTimestamp":1792029180,"startTime":"0","endTime":"0","summary":"模拟交易客户端10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。劲方医药-B盘中涨超8%，截至发稿，股价回落现小涨1.82%，报26.82港元，成交额5595.19万港元。10月15日，劲方医药-B发布公告，GFH375/VS-7375多项国内及海外临床研究取得积极进展并公布相关研究的最新数据。目前GFH375已获得国内治疗KRAS G12D突变型胰腺癌、非小细胞肺癌、结直肠癌的三项突破性疗法认定，并进入单药治疗胰腺癌及NSCLC两项注册性III期研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-15/doc-inivhiep7422940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","09939","BK1574","159938","BK1515","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675379245","title":"港股异动 | 劲方医药-B(02595.HK)涨超4% GFH375/VS-7375多项国内及海外临床研究取得积极进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2675379245","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675379245?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:40","pubTimestamp":1792028411,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1574","BK1161","09939","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675637324","title":"劲方医药-B(02595)：GFH375/VS-7375多项国内及海外临床研究取得积极进展，在多种 RAS 突变实体瘤中显示优秀疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2675637324","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675637324?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:02","pubTimestamp":1792022533,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，GFH375/VS-7375 多项国内及海外临床研究取得积极进展并公布相关研究的最新数据。目前 GFH375 已获得国内治疗 KRAS G12D 突变型胰腺癌、非小细胞肺癌 、结直肠癌的三项突破性疗法认定，并进入单药治疗胰腺癌及 NSCLC 两项注册性 III 期研究 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159938","02595","BK1515","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675377294","title":"天风·医药 | 创新药/制药行业及个股2026半年度回顾与展望——天风医药细分领域分析与展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2675377294","media":"天风研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675377294?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:00","pubTimestamp":1792022400,"startTime":"0","endTime":"0","summary":"BD交易落地和新药获批上市销售放量共同驱动行业发展。2026H1制药板块业绩整体承压传统制药板块合计136家上市公司，2026H1板块整体营业收入为2519.04亿元，同比减少1.17%；归母净利润为319.44亿元，同比减少0.48%；扣非归母净利润为274.99亿元，同比减少6.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzAwMzIzNzcwMg==&mid=2649154817&idx=2&sn=0a1cd07b7d3d89252231370cfa968fb0&chksm=824cbd8ebc17e106a1b90108ebd30406c413fafca7ee07c39922924bf9bccb39e6bfc4c3b943&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["MEDX","BK1161","159992","BK1515","LNGR","09939","BK1574","IBBQ","06978","AGNG","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675237863","title":"美股收盘：三大指数齐跌，纳指跳水超510点跌1.88%；半导体、光通信、存储芯片板块集体重挫；科技股普跌，苹果市值创新高；医药股逆市大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2675237863","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675237863?lang=zh_cn&edition=full","pubTime":"2026-10-15 06:40","pubTimestamp":1792017617,"startTime":"0","endTime":"0","summary":"美东时间周三（14日），受通胀数据恶化影响，美国三大股指集体收跌。截至收盘，纳指跌1.88%，跌超510点，创7月23日以来最大单日跌幅；道指跌0.09%，标普500指数跌1.11%。大型科技股普跌，META、英伟达跌超3%，特斯拉跌超2%，微软、谷歌跌超1%；苹果涨0.5%，市值首次收于5万亿美元以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610153895903528.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610153895903528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["QQQI","XSD","MQQQ","TEKX",".IXIC","CHPS","SOXL","09747","09939","SOXQ","LYTE","FOTO","MNQmain","159582","LUMA","USD","SOXS","CHPY","VGT","SQQQ","TQQQ","NBDS","HBMX","CWC","SSG","SIXG","RAM","TECY","FWD","FTXL","XLK","ROM","SOXY","DRMP","SOXX","159659","QYLG","03086","SMH","159938","SMHX","DRMY","QQQ","MUD","TTTN","PSI","EIS","DISK","DRAM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0795},{"period":"1month","weight":-0.1995},{"period":"3month","weight":-0.1301},{"period":"6month","weight":-0.4487},{"period":"1year","weight":-0.3},{"period":"ytd","weight":-0.2321}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.174983},{"month":3,"riseRate":0.333333,"avgChangeRate":0.058562},{"month":4,"riseRate":0.666667,"avgChangeRate":0.374359},{"month":5,"riseRate":0.5,"avgChangeRate":0.006013},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.081543},{"month":7,"riseRate":0.571429,"avgChangeRate":0.098094},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.060443},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.106422},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.109191},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}